Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|May 4, 2021

Isolation of Tumor-Infiltrating Lymphocytes from Dissociated Tumor Cells

Author(s)BioIVT

Tumor-infiltrating lymphocytes may hold the key to treating solid tumors with cell therapies, and BioIVT’s DTC product line is a great source for TILs. In this white paper, you’ll read about defining what TILs are, their potential therapeutic applications, the characterization of BioIVT’s current donor pool by TIL content and the frequency of TILs by tumor tissue type.


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.